logo
Patient, advocates worry shuttered mental health program for Toronto's Chinese community will reduce access

Patient, advocates worry shuttered mental health program for Toronto's Chinese community will reduce access

Yahoo6 days ago
A Toronto woman and health advocates are worried the Chinese community will lose access to culturally sensitive mental health care after a specialized program at Toronto Western Hospital was shuttered and subsumed into a larger outpatient mental health service for underrepresented communities.
But the University Health Network says the Asian Initiative in Mental Health (AIM) program hasn't shut down. Instead, it has been integrated into the larger program to provide care to more people, says Ishrat Husain, UHN's department head and program director for mental health.
Joy Luk says the first time she heard AIM "had been closed" was in mid-July during an appointment with her psychiatrist, who warned her she might be switched to another physician.
She says her doctor told her she could no longer access Cantonese-speaking psychotherapists, who were allegedly fired with the program's closure.
While Husain confirmed there were some "staffing changes," he says patients will still have access to their psychiatrists.
"I'm under great pressure, whether they'll stop my service [and] when?" Luk said.
Luk says she saw more than 10 psychiatrists when she was admitted to Toronto Western in 2022 for struggles with depression.
WATCH | UHN shutters mental health program that served Chinese community:
She says many doctors did not understand the context of her experiences as a blind woman in her home country of Hong Kong.
That all changed, she says, when she gained access to a psychiatrist who could speak Cantonese and understood the cultural nuances of the Chinese community through the AIM program.
"It's so difficult to explain in English the deepest part of my mind," said Luk, who moved to Canada in 2021.
"It's very important for a psychiatrist to understand the background and the underlying situation of a patient, especially, we Chinese have specific family teachings."
Luk says the "one stop shop" service gave her access to Cantonese-speaking doctors, group therapies and other mental health supports, but now she's unsure how her care will change.
Change meant to 'modernize' access to care: doctor
UHN is hoping the change will shorten wait times for initial assessments from six months to a few weeks, says Husain.
The outpatient program will have four Mandarin and Cantonese-speaking doctors, while AIM only had two, he says.
"The change was to actually modernize and make our mental health program more responsive to the population that we're serving," he said.
Once the program shift was announced, Husain says patients were individually contacted to answer questions and address any concerns.
"Change can be difficult for a lot of folks," he said. "We've been doing outreach to patient groups, community partners, referring physicians as well to be able to, to quell some of that anxiety."
Only hospital-based program for minorities in Toronto: psychiatrist
But despite what Husain says about the program integration, psychiatrist Ted Lo says he considers AIM to be closed as it no longer has the same name, allegedly lost half of its staff and has left patients confused in the aftermath. Lo is with the RE-AIM coalition, a group that aims to consult with UHN to restore the program.
He says UHN's response to AIM's closure is "all words."
"The program that has run for 23 years has served a lot of Chinese patients, but not just serving them, but serving in a way that is culturally safe and effective," he said.
AIM was the only hospital-based mental health program that served a specific minority population in Toronto, and likely all of Canada, says Lo.
Josephine Wong, another member of the RE-AIM coalition, says the hospital should've consulted patients, staff and community partners prior to the change.
"This kind of providing services to all is a sugar coated way to say that let's just get rid of those who cannot really voice for themselves and we just do whatever we want," she told CBC Radio's Metro Morning.
Husain says UHN is happy to meet with RE-AIM to talk about their concerns, but asserts the program has "not gone away."
Consultations were not held before the change as UHN felt it would have "minimal impact on patient care," he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21
SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21

Yahoo

time23 minutes ago

  • Yahoo

SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21

OVERLAND PARK, Kan., August 07, 2025--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fourth quarter and full year 2025 financial results before market open on Thursday, August 21, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (August 21, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website or via this link. About SelectQuote: Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care. With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs. View source version on Contacts Investor Relations: Sloan Bohlen877-678-4083investorrelations@ Media: Matt Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Common Painkiller Tied to Heart Failure Risk in Older Adults
Common Painkiller Tied to Heart Failure Risk in Older Adults

Medscape

time24 minutes ago

  • Medscape

Common Painkiller Tied to Heart Failure Risk in Older Adults

The antiseizure medication pregabalin, which is commonly prescribed for chronic pain, has been linked to an increased risk for heart failure (HF), particularly in those with a history of cardiovascular disease (CVD), new data suggested. In a cohort of more than 240,000 Medicare beneficiaries with noncancer chronic pain, initiation of pregabalin was associated with a 48% higher risk for new-onset HF overall and an 85% higher risk in those with a history of CVD than initiation of gabapentin. The study was published online on August 1 in JAMA Network Open . Widely Prescribed Medications Chronic pain affects up to 30% of adults aged 65 years or older. Nonopioid medications, such as the gabapentinoids pregabalin and gabapentin, are widely prescribed for chronic pain, the investigators, led by Elizabeth Park, MD, Columbia University Irving Medical Center in New York City, noted. Pregabalin has greater potency than gabapentin in binding to the α2δ subunit of the L-type calcium channel and therefore may be associated with an increased risk for HF through actions to cause sodium/water retention. To investigate further, investigators evaluated 246,237 Medicare beneficiaries between 2014 and 2018, including 18,622 (8%) new pregabalin users and 227,615 (92%) new gabapentin users. All patients were aged 65-89 years, had chronic noncancer pain, and had no history of HF. The researchers used inverse probability of treatment weighting to adjust for an extensive list of 231 covariates to reduce confounding and attempted to closely emulate a hypothetical target trial in which Medicare patients filled new prescriptions for pregabalin or gabapentin for noncancer pain. During 114,113 person-years of follow-up, 1470 patients had a hospital admission or emergency department visit for HF. The rate of HF per 1000 person-years was 18.2 for pregabalin and 12.5 — translating to roughly six additional HF events annually for every 1000 patients treated with pregabalin — with an adjusted hazard ratio (HR) of 1.48. The difference was even more pronounced in patients with a history of CVD, with an adjusted HR of 1.85. An increased risk for outpatient HF diagnoses was also seen (adjusted HR, 1.27), but there was no difference in all-cause mortality between groups. The authors said the findings further support current recommendations from the European Medicines Agency to exercise caution when prescribing pregabalin to older adults with CVD. The American Heart Association currently lists pregabalin, but not gabapentin, as a medication that may cause or exacerbate HF. Immediate Clinical Implications The co-authors of an invited commentary noted that the study provides 'timely and clinically relevant insights' into the cardiovascular safety of these two widely used gabapentinoids. From a clinical standpoint, the findings have 'immediate clinical implications,' wrote Robert Zhang, MD, with Weill Cornell Medicine, New York City, and Edo Birati, MD, Tzafon (Poriya) Medical Center, Poriya, Israel. For older adults with chronic pain, particularly those with CVD, 'clinicians should weigh the potential cardiovascular risks associated with pregabalin against its analgesic benefits. This is particularly relevant given the growing use of gabapentinoids in older populations and ongoing polypharmacy issues in this age group,' Zhang and Birati advised. 'Furthermore, if pregabalin use is associated with new-onset HF, it raises the possibility that the drug may unmask underlying subclinical cardiovascular disease, which suggests a need for careful cardiac evaluation prior to prescribing this medication,' they added. 'The study serves as an important reminder that not all gabapentinoids are created equal and that in the pursuit of safer pain control, vigilance for unintended harms remains paramount,' the investigators concluded.

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Yahoo

timean hour ago

  • Yahoo

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store